United States Alzheimer’S Disease Diagnostics Market Size By Diagnostics Test (PET, SPECT, Blood Based ELISA Test, CSF Assays), By End-User (Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers), And Forecast
Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format
View Details Download Sample Ask for Discount Request CustomizationUnited States Alzheimer’S Disease Diagnostics Market Size By Diagnostics Test (PET, SPECT, Blood Based ELISA Test, CSF Assays), By End-User (Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers), And Forecast
United States Alzheimer’S Disease Diagnostics Market Size And Forecast
The market size of the United States Alzheimer’s Disease Diagnostics Market stood at USD 1,211.63 Million in 2022 and is projected to reach USD 1,768.10 Million by 2030, growing at a CAGR of 6.50% from 2024 to 2030.
The growing elderly population worldwide is one of the main factors driving the market for diagnostics for Alzheimer’s disease. In Addition, the precision and reliability of diagnosing Alzheimer’s disease have increased due to the introduction of innovative imaging tools, genetic testing procedures, and biomarkers. These developments influence the use of diagnostic tools and tests in clinical practice. The United States report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.
United States Alzheimer’S Disease Diagnostics Executive Summary
The Alzheimer’s disease is a neurological disease that frequently begins with moderate symptoms before getting progressively worse. It is a kind of dementia that becomes worse over time and is characterized by a person’s ability to function independently in everyday activities while their cognitive, behavioural, and social abilities progressively decrease. Alzheimer’s disease affects language and thought-controlling regions of the brain.
Based on Diagnostic Type, the U.S. Alzheimer’s Disease Market has been segmented SPECT, Positron Emission Tomography, Blood based ELISA Test, CSF Assays, Others. The Positron Emission Tomography is holding the largest share of the market. Moreover, based on End User, the U.S. Alzheimer’s Disease Market has been segmented into Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center. The Hospital segment is holding the highest market share.
Cognitive decline, memory loss, and behavioural abnormalities are symptoms of Alzheimer’s disease (AD), a progressive neural condition. Accurate and early diagnosis are more essential than ever as the prevalence of AD increases in the country. The growing elderly population worldwide is one of the main factors driving the market for diagnostics for Alzheimer’s disease. Most AD victims are older, and as life expectancy increases, more people become vulnerable to the disease. As the population ages, cognitive deficits become more common, making early and precise diagnosis crucial for prompt intervention and treatment.
Furthermore, AD prevalence has been rising rapidly, especially in rich countries. The prevalence of AD is rising due to some factors, including sedentary lifestyles, bad diets, and a lack of preventative measures. Due to the rise in occurrence, there is an increased need for efficient diagnostic techniques to detect diseases at their earliest stages, when treatment is most effective. In Addition, the precision and reliability of diagnosing Alzheimer’s disease have increased due to the introduction of innovative imaging tools, genetic testing procedures, and biomarkers. These developments influence the use of diagnostic tools and tests in clinical practice.
The price and accessibility of diagnostic techniques are two significant barriers to the market for Alzheimer’s disease diagnosis. Advanced imaging methods are costly and challenging to acquire in many hospital settings. Particularly in areas with low resources, high costs, and restricted availability, prevent widespread adoption and delay early diagnosis. Moreover, huge investments and the risk of failure can hamper market growth. Government programs, initiatives, or funds that promote innovation and market development for Alzheimer’s disease diagnostics provide market expansion prospects.
What's inside a
industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
United States Alzheimer’S Disease Diagnostics MarketSegmentation Analysis
The United States Alzheimer’S Disease Diagnostics Market is segmented based on Diagnostics Test, and End-User.
United States Alzheimer’S Disease Diagnostics Market, By Diagnostics Test
To Get a Summarized Market Report By Diagnostic Test-
Based on Diagnostic Test, the market is segmented into PET, SPECT, Blood Based ELISA Test, CSF Assays, and Others. The US Alzheimer’S Disease Diagnostics Market is experiencing a scaled level of attractiveness in the PET segment. PET accounted for the largest market share of 35.67% in 2022, with a market value of USD 378.76 Million, and is projected to grow at a CAGR of 5.92% during the forecast period. SPECT was the second-largest market in 2022, Value of USD 258.58 Million in 2022; it is projected to grow at a CAGR of 6.17%. However, CSF Assays is projected to grow at the highest CAGR of 8.38%.
In Alzheimer’s disease (AD), positron emission tomography (PET) is a crucial diagnostic procedure. PET uses a radiotracer, a radioactive chemical that releases positrons, to see the metabolic activity in the brain. Fluorodeoxyglucose (FDG), which assesses glucose metabolism, is one of the radiotracers frequently employed in diagnosing AD. Reduced glucose metabolism in particular brain areas, notably the temporal and parietal lobes, is a symptom of AD. These metabolic anomalies may be found and differentiated between AD and other types of dementia using PET-FDG imaging. Early AD identification is essential for better symptom management and appropriate treatments.
Furthermore, PET scans using tau-specific radiotracers can be used to visualize tau protein clumps, a crucial pathogenic characteristic of AD. These tracers, including AV-1451, commonly called T807 or flortaucipir, attach only to the tau tangles in the brain. While used to stage diseases, monitor disease development, and assess the efficacy of experimental therapies that target tau, tau imaging sheds light on the degree and distribution of tau pathology.
United States Alzheimer’S Disease Diagnostics Market, By End-User
To Get a Summarized Market Report By Geography-Â
Based on End-User, the market is segmented into Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers. The US Alzheimer’S Disease Diagnostics Market is experiencing a scaled level of attractiveness in the Hospitals segment. Hospitals accounted for the largest market share of 30.93% in 2022, with a market value of USD 328.40 Million, and is projected to grow at a CAGR of 5.85% during the forecast period. Diagnostic Centers were the second-largest market in 2022, Value of USD 298.02 Million in 2022; it is projected to grow at the highest CAGR of 7.68%.
The patients often visit a hospital for a proper diagnosis of Alzheimer’s disease. Furthermore, healthcare professionals recommend a treatment regimen to help maintain the patient’s quality of life, therefore providing better access to Alzheimer’s disease diagnosis and treatment. Hospitals are equipped with significant scanning equipment for Alzheimer’s diagnosis. However, there is no single test for the complete diagnosis of Alzheimer’s disease, and the complete diagnosis of the disease requires various approaches and tools with the help of several specialists such as – neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists. Accurate diagnosis, ideal therapy planning, and continuing patient monitoring are made accessible through the collaboration of these professionals.
Key Players
The major players in the market are; GE Healthcare, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Quanterix, Sysmex, Eli Lilly & Company, C2N Diagnostics, Randox, MagQu Co. Ltd., Neuro-Bio Ltd, Pre-Diagnostics AS, Fujirebio and others. This section provides company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.
Company Market Ranking Analysis
The company ranking analysis provides a deeper understanding of the top 3 players operating Alzheimer’s Disease Diagnostics market. takes into consideration several factors before providing a company ranking. The top three players in the Alzheimer’s Disease Diagnostics market are GE Healthcare, Siemens Healthineers AG, and F. Hoffmann-La Roche Ltd. The factors considered for evaluating these players include company’s brand value, product portfolio (including product variations, specifications, features, and price), company presence across major regions, product-related sales obtained by the company in recent years, and its share in the total revenue. further studies the company’s product portfolio based on the technologies adopted or new strategies undertaken by the company to enhance its market presence in US or regionally. We also consider the End-Users (Hospitals, Diagnostic Centers, Pharmaceutical Companies, Clinics, and Academic Research Centers) of the company help us to understand the company’s presence and foothold in various Alzheimer’s Disease Diagnostics markets.
Company Regional/Industry Footprint
The company’s regional section provides geographical presence, regional level reach, or the respective company’s sales network presence. For instance, GE Healthcare Company Inc. has a presence in the US.Apart from this, the industrial footprint section provides a cross-analysis of industry verticals and market players that gives a clear picture of the company landscape concerning the industries they serve their products. The product portfolio of the companies is classified in terms of their diversification as well as the number of products/services that are available. The geographic reach and the market penetration are determined considering the penetration of the company’s products and services in various geographical regions and industries.
Ace Matrix
This section of the report provides an overview of the company evaluation scenario in the Alzheimer’s Disease Diagnostics market. The company evaluation has been carried out based on the outcomes of the qualitative and quantitative analyses of various factors such as the product portfolios, technological innovations, market presence, revenues of companies, and the opinions of primary respondents.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| STUDY PERIOD | 2019-2030 |
| BASE YEAR | 2022 |
| FORECAST PERIOD | 2024-2030 |
| HISTORICAL PERIOD | 2019-2021 |
| UNIT | Value (USD Million) |
| KEY COMPANIES PROFILED | GE Healthcare, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Quanterix, Sysmex, Eli Lilly & Company, C2N Diagnostics, Randox, MagQu Co. Ltd., Neuro-Bio Ltd, Pre-Diagnostics AS, Fujirebio and others. |
| SEGMENTS COVERED | Diagnostics Test, and End-User. |
| CUSTOMIZATION SCOPE | Free report customization (equivalent up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
To Get Customized Report Scope-Â
Top Trending Reports
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support
Customization of the Report
• In case of any  please connect with our sales team, who will ensure that your requirements are met.
Table of Content
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
List Tables Figures
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy